Tower Research Capital LLC (Trc) Aptinyx Inc. Transaction History

Tower Research Capital LLC (Trc)

  • $3.68 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$0.12 - $0.69 $2,306 - $13,259
19,217 Added 70.92%
46,312 $6,000
Q4 2022

Feb 10, 2023
BUY
$0.23 - $0.34 $6,231 - $9,212
27,095 New
27,095 $8,000
Q2 2022

Aug 15, 2022
BUY
$0.38 - $2.58 $486 - $3,299
1,279 Added 28.47%
5,772 $3,000
Q1 2022

May 12, 2022
SELL
$2.27 - $3.62 $23,017 - $36,706
-10,140 Reduced 69.3%
4,493 $10,000
Q4 2021

Feb 14, 2022
BUY
$2.11 - $3.0 $15,862 - $22,554
7,518 Added 105.66%
14,633 $39,000
Q3 2021

Nov 15, 2021
BUY
$2.21 - $2.89 $15,717 - $20,553
7,112 Added 237066.67%
7,115 $17,000
Q2 2021

Aug 16, 2021
SELL
$2.39 - $3.5 $27,198 - $39,830
-11,380 Reduced 99.97%
3 $0
Q1 2021

May 17, 2021
BUY
$2.86 - $4.33 $14,285 - $21,628
4,995 Added 78.19%
11,383 $35,000
Q4 2020

Feb 16, 2021
SELL
$2.93 - $4.3 $50,557 - $74,196
-17,255 Reduced 72.98%
6,388 $22,000
Q3 2020

Nov 16, 2020
BUY
$3.05 - $4.99 $5,078 - $8,308
1,665 Added 7.58%
23,643 $80,000
Q2 2020

Aug 13, 2020
BUY
$1.99 - $4.4 $39,338 - $86,979
19,768 Added 894.48%
21,978 $92,000
Q1 2020

May 15, 2020
SELL
$1.81 - $5.03 $2,774 - $7,710
-1,533 Reduced 40.96%
2,210 $5,000
Q4 2019

Feb 07, 2020
SELL
$2.84 - $4.25 $50,287 - $75,254
-17,707 Reduced 82.55%
3,743 $13,000
Q3 2019

Nov 05, 2019
BUY
$3.0 - $4.08 $50,373 - $68,507
16,791 Added 360.4%
21,450 $75,000
Q2 2019

Aug 13, 2019
SELL
$2.95 - $4.38 $5,823 - $8,646
-1,974 Reduced 29.76%
4,659 $16,000
Q1 2019

May 14, 2019
BUY
$3.99 - $19.33 $17,759 - $86,037
4,451 Added 203.99%
6,633 $27,000
Q4 2018

Feb 14, 2019
BUY
$16.15 - $28.93 $35,239 - $63,125
2,182 New
2,182 $36,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email